Company · CIK 0001407038 · SIC 2835 — In Vitro & In Vivo Diagnostic Substances
BG Medicine, Inc. · BGMD
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2016 FForm 4 → | Apr 4, 8:35 pm EDT | Paul R SohmerPresident & CEO, Director | 15,493 | $0.36 | $5,577 | 53,161 | — | plan? |
| Mar 31, 2016 FForm 4 → | Apr 4, 8:33 pm EDT | Stephen P HallEVP & Chief Financial Officer | 8,986 | $0.36 | $3,235 | 31,034 | — | plan? |
| Mar 31, 2016 FForm 4 → | Apr 4, 8:29 pm EDT | Aram S. AdourianSVP & Chief Scientific Officer | 7,456 | $0.36 | $2,684 | 35,770 | — | plan? |
| Dec 9, 2015 SForm 4 → | Dec 11, 4:23 pm EST | Noubar AfeyanDirector, 10% Owner | 46,438 | $0.56 | $26,005 | 0 | −100% | plan? |
| Aug 15, 2015 FForm 4/A → | Apr 4, 2016, 8:26 pm EDT | Stephen P HallEVP & Chief Financial Officer | 7,530 | $0.83 | $6,250 | 40,020 | — | plan? |
| Aug 15, 2015 FForm 4/A → | Apr 4, 2016, 8:21 pm EDT | Aram S. AdourianSVP & Chief Scientific Officer | 6,233 | $0.83 | $5,173 | 43,226 | — | plan? |
| Aug 15, 2015 FForm 4 → | Aug 19, 8:22 pm EDT | Aram S. AdourianSVP & Chief Scientific Officer | 6,233 | $0.83 | $5,173 | 40,226 | — | plan? late amended |
| Aug 15, 2015 FForm 4 → | Aug 19, 8:17 pm EDT | Stephen P HallEVP & Chief Financial Officer | 7,505 | $0.83 | $6,229 | 39,995 | — | plan? late amended |
| Aug 15, 2015 FForm 4 → | Aug 19, 8:14 pm EDT | Paul R SohmerPresident & CEO, Director | 13,321 | $0.83 | $11,056 | 68,654 | — | plan? late |
| Jul 27, 2015 SForm 4 → | Jul 29, 4:46 pm EDT | Noubar Afeyan +4Director, 10% Owner | 302 | $2.27 | $686 | 58,232 | −0.52% | plan? |
| Jul 27, 2015 XForm 4 → | Jul 29, 4:46 pm EDT | Noubar Afeyan +4Director, 10% Owner | 4,780 | $0.14 | $669 | 58,264 | — | plan? |
| Jul 27, 2015 SForm 4 → | Jul 29, 4:41 pm EDT | Noubar Afeyan +4Director, 10% Owner | 4,980 | $2.27 | $11,305 | 786,970 | −0.63% | plan? |
| Jul 27, 2015 XForm 4 → | Jul 29, 4:41 pm EDT | Noubar Afeyan +4Director, 10% Owner | 79,087 | $0.14 | $11,072 | 787,500 | — | plan? |
| Apr 14, 2014 MForm 4 → | May 4, 2016, 6:15 pm EDT | Aram S. AdourianSVP & Chief Scientific Officer | 12,000 | $0.90 | $10,800 | 40,036 | — | plan? late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2016 AForm 4 → | Feb 5, 7:36 pm EST | Jeffrey R LuberDirector | 10,000 | — | — | 10,000 | — | |
| Nov 18, 2015 AForm 4 → | Nov 20, 5:49 pm EST | Harry W WilcoxDirector | 5,000 | — | — | 5,000 | — | |
| Nov 18, 2015 AForm 4 → | Nov 20, 5:46 pm EST | Stelios PapadopoulosDirector | 5,000 | — | — | 5,000 | — | |
| Nov 18, 2015 AForm 4 → | Nov 20, 5:44 pm EST | Noubar AfeyanDirector, 10% Owner | 5,000 | — | — | 5,000 | — | |
| Jul 27, 2015 XForm 4 → | Jul 29, 4:46 pm EDT | Noubar Afeyan +4Director, 10% Owner | 4,780 | — | — | 0 | — | |
| Jul 27, 2015 XForm 4 → | Jul 29, 4:41 pm EDT | Noubar Afeyan +4Director, 10% Owner | 79,087 | — | — | 0 | — | |
| Jul 14, 2015 CJPForm 4 → | Jul 16, 5:33 pm EDT | Noubar Afeyan +8Director, 10% Owner | 1,474,443 | $1.70 | $1,999,998 | 497,729 | — | |
| Feb 20, 2015 AForm 4 → | Feb 24, 6:18 pm EST | Stephen P HallEVP & Chief Financial Officer | 140,000 | — | — | 140,000 | — | |
| Feb 20, 2015 AForm 4 → | Feb 24, 6:18 pm EST | Paul R SohmerPresident & CEO, Director | 200,000 | — | — | 200,000 | — | |
| Feb 20, 2015 AForm 4 → | Feb 24, 6:18 pm EST | Aram S. AdourianSVP & Chief Scientific Officer | 140,000 | — | — | 140,000 | — | |
| Apr 14, 2014 MForm 4 → | May 4, 2016, 6:15 pm EDT | Aram S. AdourianSVP & Chief Scientific Officer | 12,000 | — | — | 16,036 | — | late |